Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering
November 15, 2021 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
November 09, 2021 16:01 ET
|
Cyclerion Therapeutics, Inc.
First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment...
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
September 22, 2021 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function,...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
September 01, 2021 19:45 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
August 23, 2021 17:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
July 29, 2021 17:00 ET
|
Cyclerion Therapeutics, Inc.
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive...
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
June 16, 2021 09:00 ET
|
Headlands Research
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- Headlands Research (www.headlandsresearch.com), a global next-generation clinical research site organization, is pleased to have supported Biogen...
Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board
April 20, 2021 11:31 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, April 20, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage...
Alzheimer’s Disease Treatment Market Value Predicted To Reach US$ 5,647.5 Million By 2027: Acumen Research And Consulting
April 07, 2021 10:12 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Alzheimer’s Disease Treatment Market– Global Industry Analysis, Market Size,...
Global Alzheimer’s Treatment Market to Touch USD 2008.17 Million in 2027; Alzheimer’s Treatment Market in North America to Bring in Highest Revenue of around USD 500 Million in 2020
November 02, 2020 08:20 ET
|
Research Nester
New York, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Causing disability majorly among older people, Alzheimer’s disease contributes to 60-70% of dementia cases, currently amounting to around 50 million cases...